NCT00814606

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study seeks to evaluate the safety and efficacy of taking fluvastatin along with peginterferon alfa in previous partial responders with genotype 1 HCV.

Conditions

• Hepatitis C
• Hepatitis C Virus

Interventions

Type	Name	Description
DRUG	Fluvastatin	Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
DRUG	Peginterferon alfa2a	180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
DRUG	ribavirin	1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)

Timeline

• Start date: 2010-02-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2008-12-25
• Last updated: 2013-07-01